KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to $919.0 million.

  • Bristol Myers Squibb's Tax Provisions rose 9934.92% to $919.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 44141.69%. This contributed to the annual value of $554.0 million for FY2024, which is 3850.0% up from last year.
  • As of Q3 2025, Bristol Myers Squibb's Tax Provisions stood at $919.0 million, which was up 9934.92% from $460.0 million recorded in Q2 2025.
  • In the past 5 years, Bristol Myers Squibb's Tax Provisions ranged from a high of $919.0 million in Q3 2025 and a low of -$514.0 million during Q4 2021
  • Over the past 5 years, Bristol Myers Squibb's median Tax Provisions value was $460.0 million (recorded in 2025), while the average stood at $278.6 million.
  • As far as peak fluctuations go, Bristol Myers Squibb's Tax Provisions crashed by 14120.98% in 2023, and later skyrocketed by 21557.79% in 2025.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's Tax Provisions stood at -$514.0 million in 2021, then soared by 67.7% to -$166.0 million in 2022, then soared by 46.99% to -$88.0 million in 2023, then skyrocketed by 212.5% to $99.0 million in 2024, then skyrocketed by 828.28% to $919.0 million in 2025.
  • Its Tax Provisions was $919.0 million in Q3 2025, compared to $460.0 million in Q2 2025 and $509.0 million in Q1 2025.